UnitedHealth Program Aims to Give Employers More Bang for Their GLP-1 Bucks
-
Nov 26, 2024
Employer plan sponsors in recent years have struggled to contain the costs associated with the increasing demand from beneficiaries to use GLP-1 medications for obesity and diabetes. For instance, Aon, a health benefits consultant, found there was an 87% increase in spending on GLP-1 drugs in 2023 due to higher utilization. And JPMorgan analysts predict the GLP-1 market could exceed $100 billion by 2030, when 30 million U.S. residents (or 9% of the population) could be taking the medications.
To address the growing obesity treatment market, UnitedHealthcare is offering the Total Weight Support program for self-insured employers. Rhonda Randall, M.D., chief medical officer for UnitedHealthcare’s commercial business, says managing weight loss drug costs “has been a significant priority for us and our employer customers.”
Read more
© 2024 MMIT
Related Posts
-
![]()
Oct 04
Benefits Execs Say Higher Provider Pay, Drug Costs Are Fueling 2025 Health Cost Hike
Read more -
![]()
May 23
Plans Take Wait-and-See Approach to Vendors Promising Help With Weight Loss Medication Costs
Read more -
![]()
Jun 27
PSG Survey Finds 33% of Health Plans, Employers Cover GLP-1s for Obesity
Read more
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.